Abbott to Acquire Exact Sciences Following Strong Q3 and Cancerguard Launch

Introduction

Exact Sciences Corp. (Nasdaq: EXAS) is a molecular diagnostics company headquartered in Madison, Wisconsin, focused on the detection and prevention of early-stage cancers. Its portfolio includes Cologuard®, a non-invasive stool DNA test for colorectal cancer; Oncotype DX®, a precision oncology assay; and Cancerguard®, a multi-cancer early detection (MCED) test.

Corporate Structure and Operations

Exact Sciences employs over 6,500 individuals across more than 120 countries. The company maintains nine research and development centers and operates laboratories equipped with advanced technologies. In 2023, it processed over 4 million tests. Exact Sciences has been certified as a Great Place To Work® for seven consecutive years and sustains partnerships with healthcare providers, researchers, and advocacy organizations.

Cancer Detection by Milad Fakurian

Recent Developments and News

• September 2025: Launch of Cancerguard® MCED test, supported by data from DETECT-A and ASCEND 2 studies involving more than 20,000 participants.
• November 3, 2025: Third quarter results for the period ending September 30:
  • Total revenue of $851 million, a 20% increase year-over-year
  • Screening revenue of $666 million (+22%) and Precision Oncology revenue of $184 million (+13%)
  • Gross margin at 69% (adjusted 71%)
  • Net loss of $20 million, or $0.10 per share (improvement of $19 million compared to the same period of the prior year)
  • Adjusted EBITDA of $135 million (+37%), with a 16% margin
  • Operating cash flow of $220 million (+59%) and free cash flow of $190 million (+69%)
  • Cash, cash equivalents, and marketable securities totaling $1.00 billion at quarter end
  • Raised full-year 2025 revenue guidance midpoint by $78 million and adjusted EBITDA midpoint by $10 million
• November 2025: Announcement that Abbott Laboratories will acquire Exact Sciences in a transaction valued at approximately $21 billion, at $105 per share. The deal is expected to close in Q2 2026, subject to regulatory and shareholder approvals.

Financial and Strategic Analysis

Exact Sciences’ Q3 performance reflects growth across both screening and precision oncology segments. Margin expansion and free cash flow contributed to the upward revision of 2025 guidance. The introduction of Cancerguard® broadens the test portfolio to include MCED, addressing multiple cancer types.

The pending acquisition by Abbott Laboratories offers potential benefits, including access to Abbott’s global distribution network serving over 2 billion patients annually. The integration aims to enhance commercialization of Exact Sciences’ assays worldwide. Key transaction risks include obtaining regulatory approvals, securing shareholder votes, potential competing bids, and contractual termination fees.

Market Position and Industry Context

Operating within biotechnology research and genomic testing, Exact Sciences holds a position in non-invasive colorectal screening with Cologuard® and precision oncology decision support with Oncotype DX®. The MCED sector is increasingly competitive, with blood-based assays in development by various firms. FDA approvals are critical for market access. Collaborations with academic institutions and advocacy groups support the adoption of its tests. The acquisition by Abbott aligns with consolidation trends in the diagnostics industry, as larger companies seek to integrate innovative testing platforms to expand cancer screening offerings.

tl;dr

On November 3, 2025, Exact Sciences reported Q3 revenue of $851 million (up 20% YoY), net loss of $20 million, and adjusted EBITDA of $135 million. In September 2025, the company launched Cancerguard®, its MCED test. Abbott Laboratories agreed in November 2025 to acquire Exact Sciences for approximately $21 billion, with closing expected in Q2 2026 pending approvals.